Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.38 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | VDR | P11473 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21149355 | 1.00 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL23832592 | 1.00 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL1016996 | 1.00 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL25362116 | 1.00 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL8926866 | 1.00 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL23015111 | 1.00 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL25371249 | 1.00 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL2845979 | 0.98 | CA12 (0.40) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL278880 | 0.94 | ALDH1A1 (0.41) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL31173815 | 0.90 | ALDH1A1 (0.40) | CA12CA1CA9ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667466-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250154157-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | CANCER RESEARCH TECH LTD (GB) | 2025-05-15 | — | — | US | disclosed |
| EP-4479400-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | Cancer Research Technology Limited (GB) | 2024-12-25 | — | — | EP | disclosed |
| CN-119053604-A | Heterocyclic compounds for the treatment of ERK5 mediated diseases | 癌症研究技术有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| WO-2023156791-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023156791-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-08-24 | — | — | WO | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-10829792-B2 | Biocatalytic synthesis of strained carbocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180305721-A1 | Biocatalytic Synthesis of Strained Carbocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-10-25 | — | — | US | disclosed |
| US-8247595-B2 | Organic sulfur compound and its use for controlling harmful arthropod | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| EP-2152668-B1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPODS | SUMITOMO CHEMICAL CO (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100160434-A1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2152668-A1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD | Sumitomo Chemical Company, Limited (JP) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008143338-A1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | CA12 3736/4885CA1 4509/4885CA9 3376/4885 |
| US-20100160434-A1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD | C5, L3MBTL3, C1S | CA12 1342/4885CA1 2754/4885CA9 1372/4885 |
| US-20250154157-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | MAP3K5, MAPK1, MAP3K20 | CA12 4638/4885CA1 4617/4885CA9 4443/4885 |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | LPAR4, LPAR2, LPAR1 | CA12 3919/4885CA1 4611/4885CA9 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.